A Selective Retinoid X Receptor Agonist Bexarotene (LGD1069, Targretin) Inhibits Angiogenesis and Metastasis in Solid Tumours

Overview

Journal Br J Cancer

Specialty Oncology

Date 2006 Feb 24

PMID 16495926

Citations 20

Authors

W-C Yen

R Y Prudente

M R Corpuz

A Negro-Vilar

W W Lamph

Affiliations

Soon will be listed here.

Abstract

The present study determined the influence of a retinoid X receptor agonist bexarotene on angiogenesis and metastasis in solid tumours. In the experimental lung metastasis xenograft models, treatment with bexarotene inhibited the development of the lung tumour nodule formation compared to control. In vivo angiogenesis assay utilising gelfoam sponges, bexarotene reduced angiogenesis in sponges containing vascular endothelial growth factor, epidermal growth factor and basic fibroblast growth factor to various extent. To determine the basis of these observations, human breast and non-small-cell lung cancer cells were subjected to migration and invasion assays in the presence of bexarotene. Our data showed that bexarotene decrease migration and invasiveness of tumour cells in a dose-dependent manner. Furthermore, bexarotene inhibited angiogenesis by directly inhibiting human umbilical vein endothelial cell growth and indirectly inhibiting tumour cell-mediated migration of human umbilical vein endothelial cells through Matrigel matrix. Analysis of tumour-conditioned medium indicated that bexarotene decreased the secretion of angiogenic factors and matrix metalloproteinases and increased the tissue inhibitor of matrix metalloproteinases. The ability of bexarotene to inhibit angiogenesis and metastasis was dependent on activation of its heterodimerisation partner peroxisome proliferator-activated receptor gamma. Collectively, our results suggest a role of bexarotene in treatment of angiogenesis and metastasis in solid tumours.

Citing Articles

Fatty acid oxidation is a druggable gateway regulating cellular plasticity for driving metastasis in breast cancer.

Loo S, Toh L, Xie W, Pathak E, Tan W, Ma S Sci Adv. 2021; 7(41):eabh2443.

PMID: 34613780 PMC: 8494440. DOI: 10.1126/sciadv.abh2443.

The novel rexinoid MSU-42011 is effective for the treatment of preclinical Kras-driven lung cancer.

Moerland J, Zhang D, Reich L, Carapellucci S, Lockwood B, Leal A Sci Rep. 2020; 10(1):22244.

PMID: 33335263 PMC: 7746742. DOI: 10.1038/s41598-020-79260-8.

The potential of retinoids for combination therapy of lung cancer: Updates and future directions.

Tripathi S, Pandey K, Panda M, Spinella M, Rengasamy K, Biswal B Pharmacol Res. 2019; 147:104331.

PMID: 31254665 PMC: 7066582. DOI: 10.1016/j.phrs.2019.104331.

A retinoid X receptor partial agonist attenuates pulmonary emphysema and airway inflammation.

Morichika D, Miyahara N, Fujii U, Taniguchi A, Oda N, Senoo S Respir Res. 2019; 20(1):2.

PMID: 30606200 PMC: 6318915. DOI: 10.1186/s12931-018-0963-0.

A novel gene expression analytics-based approach to structure aided design of rexinoids for development as next-generation cancer therapeutics.

Hanish B, Hackney Price J, Kaneko I, Ma N, van der Vaart A, Wagner C Steroids. 2018; 135:36-49.

PMID: 29704526 PMC: 5977990. DOI: 10.1016/j.steroids.2018.04.009.

References

Yang W, FRUCHT H . Activation of the PPAR pathway induces apoptosis and COX-2 inhibition in HT-29 human colon cancer cells. Carcinogenesis. 2001; 22(9):1379-83. DOI: 10.1093/carcin/22.9.1379. View

Yen W, Corpuz M, Prudente R, Cooke T, Bissonnette R, Negro-Vilar A . A selective retinoid X receptor agonist bexarotene (Targretin) prevents and overcomes acquired paclitaxel (Taxol) resistance in human non-small cell lung cancer. Clin Cancer Res. 2004; 10(24):8656-64. DOI: 10.1158/1078-0432.CCR-04-0979. View

McCarty M, Baker C, Bucana C, Fidler I . Quantitative and qualitative in vivo angiogenesis assay. Int J Oncol. 2002; 21(1):5-10. View

Workman P, Balmain A, Hickman J, McNally N, Rohas A, Mitchison N . UKCCCR guidelines for the welfare of animals in experimental neoplasia. Lab Anim. 1988; 22(3):195-201. DOI: 10.1258/002367788780746467. View

Tsubouchi Y, Sano H, Kawahito Y, Mukai S, Yamada R, Kohno M . Inhibition of human lung cancer cell growth by the peroxisome proliferator-activated receptor-gamma agonists through induction of apoptosis. Biochem Biophys Res Commun. 2001; 270(2):400-5. DOI: 10.1006/bbrc.2000.2436. View

Song S, Wientjes M, Gan Y, Au J . Fibroblast growth factors: an epigenetic mechanism of broad spectrum resistance to anticancer drugs. Proc Natl Acad Sci U S A. 2000; 97(15):8658-63. PMC: 27004. DOI: 10.1073/pnas.140210697. View

Kumar R, Fidler I . Angiogenic molecules and cancer metastasis. In Vivo. 1998; 12(1):27-34. View

Gottardis M, Bischoff E, Shirley M, Wagoner M, Lamph W, HEYMAN R . Chemoprevention of mammary carcinoma by LGD1069 (Targretin): an RXR-selective ligand. Cancer Res. 1996; 56(24):5566-70. View

Motomura W, Okumura T, Takahashi N, Obara T, Kohgo Y . Activation of peroxisome proliferator-activated receptor gamma by troglitazone inhibits cell growth through the increase of p27KiP1 in human. Pancreatic carcinoma cells. Cancer Res. 2000; 60(19):5558-64. View

10.

Kitamura S, Miyazaki Y, Shinomura Y, Kondo S, Kanayama S, Matsuzawa Y . Peroxisome proliferator-activated receptor gamma induces growth arrest and differentiation markers of human colon cancer cells. Jpn J Cancer Res. 1999; 90(1):75-80. PMC: 5925976. DOI: 10.1111/j.1349-7006.1999.tb00668.x. View

11.

Worley J, Baugh M, Hughes D, Edwards D, Hogan A, Sampson M . Metalloproteinase expression in PMA-stimulated THP-1 cells. Effects of peroxisome proliferator-activated receptor-gamma (PPAR gamma) agonists and 9-cis-retinoic acid. J Biol Chem. 2003; 278(51):51340-6. DOI: 10.1074/jbc.M310865200. View

12.

Ohta K, Endo T, Haraguchi K, Hershman J, Onaya T . Ligands for peroxisome proliferator-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells. J Clin Endocrinol Metab. 2001; 86(5):2170-7. DOI: 10.1210/jcem.86.5.7493. View

13.

Yen W, Lamph W . A selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced prostate cancer. Prostate. 2005; 66(3):305-16. DOI: 10.1002/pros.20347. View

14.

Panigrahy D, Huang S, Kieran M, Kaipainen A . PPARgamma as a therapeutic target for tumor angiogenesis and metastasis. Cancer Biol Ther. 2005; 4(7):687-93. DOI: 10.4161/cbt.4.7.2014. View

15.

Stetler-Stevenson W . The role of matrix metalloproteinases in tumor invasion, metastasis, and angiogenesis. Surg Oncol Clin N Am. 2001; 10(2):383-92, x. View

16.

Boehm T, Folkman J, Browder T, OReilly M . Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature. 1997; 390(6658):404-7. DOI: 10.1038/37126. View

17.

Fauconnet S, Lascombe I, Chabannes E, Desvergne B, Wahli W, Bittard H . Differential regulation of vascular endothelial growth factor expression by peroxisome proliferator-activated receptors in bladder cancer cells. J Biol Chem. 2002; 277(26):23534-43. DOI: 10.1074/jbc.M200172200. View

18.

Rosen E, Spiegelman B . PPARgamma : a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem. 2001; 276(41):37731-4. DOI: 10.1074/jbc.R100034200. View

19.

Kubota T, Koshizuka K, Williamson E, Asou H, Said J, Holden S . Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res. 1998; 58(15):3344-52. View

20.

Wu K, Zhang Y, Xu X, Hill J, Celestino J, Kim H . The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice. Cancer Res. 2002; 62(22):6376-80. View